Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Common Equity (2016 - 2025)

Mimedx's Common Equity history spans 15 years, with the latest figure at $256.5 million for Q4 2025.

  • For Q4 2025, Common Equity rose 32.85% year-over-year to $256.5 million; the TTM value through Dec 2025 reached $256.5 million, up 32.85%, while the annual FY2025 figure was $256.5 million, 32.85% up from the prior year.
  • Common Equity for Q4 2025 was $256.5 million at Mimedx, up from $238.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $256.5 million in Q4 2025 and bottomed at -$19.5 million in Q3 2022.
  • The 5-year median for Common Equity is $706000.0 (2021), against an average of $82.3 million.
  • The largest annual shift saw Common Equity tumbled 22036.59% in 2022 before it soared 13509.62% in 2024.
  • A 5-year view of Common Equity shows it stood at $82000.0 in 2021, then crashed by 22036.59% to -$18.0 million in 2022, then skyrocketed by 893.4% to $142.7 million in 2023, then soared by 35.31% to $193.1 million in 2024, then skyrocketed by 32.85% to $256.5 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Common Equity are $256.5 million (Q4 2025), $238.9 million (Q3 2025), and $216.6 million (Q2 2025).